You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
和黃醫藥(00013.HK)將於歐洲及瑞士披露旗下藥物最新臨床數據
阿思達克 12-01 08:37
和黃醫藥(00013.HK)公布,將於12月1日至3日在新加坡舉行的2023年歐洲腫瘤內科學會亞洲年會(ESMO Asia),及於12月6日至8日在瑞士日內瓦舉行的2023年歐洲腫瘤內科學會免疫腫瘤學大會(ESMO IO),公布探索性候選藥物(口夫)(口奎)替尼(fruquintinib)、索凡替尼(surufatinib)和HMPL-295數項進行中研究的最新臨床數據。 當中,公司將公布一項多中心、開放標籤臨床試驗的數據,該研究旨在評估HMPL-295在晚期惡性實體瘤患者中的安全性、耐受性、藥物動力學和初步療效特徵,並確定最大耐受劑量(MTD)和推薦的II期劑量(RP2D)。連續給藥最大耐受劑量確定為每日一次50毫克,間歇給藥的研究正在進行中。 另將公布(口夫)(口奎)替尼和信迪利單抗(sintilimab)聯合療法在中國的籃式臨床試驗(basket clinical trial)中,子宮頸癌和非小細胞肺癌患者隊列的結果。以及披露FRESCO-2研究中,根據人種分組的亞洲和非亞洲患者亞組的療效和安全性數據。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account